PC
VKTX icon

Pier Capital’s Viking Therapeutics VKTX Stock Holding History

Pier Capital’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-57,504
Closed -$2.31M – 129
2024
Q4 		$2.31M Sell
57,504
-31,643
-35% -$1.8M 0.33% 86
2024
Q3 		$5.64M Buy
89,147
+31,908
+56% +$1.87M 0.8% 70
2024
Q2 		$3.03M Sell
57,239
-2,420
-4% -$159K 0.45% 94
2024
Q1 		$4.89M Buy
+59,659
New +$2.65M 0.67% 71
2018
Q4 		– Sell
-305,350
Closed -$5.32M – 123
2018
Q3 		$5.32M Sell
305,350
-274,503
-47% -$3.27M 0.67% 86
2018
Q2 		$5.5M Buy
+579,853
New +$3.86M 0.76% 90

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Pier Capital's VKTX Position: Q1 2025 in Review

Pier Capital sold out of Viking Therapeutics (VKTX) in Q1 2025, closing a stake of 57,504 shares — an estimated $2.31M sold.

Pier Capital first reported a position in VKTX in Q2 2018 and held it in 6 quarters. The position peaked at $5.64M in Q3 2024. 373 funds tracked by Wall St. Rank hold VKTX as of Q1 2025.

  • Pier Capital reported no remaining Viking Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Pier Capital sold 57,504 Viking Therapeutics shares in Q1 2025, an estimated $2.31M.
  • Pier Capital first reported a position in Viking Therapeutics in Q2 2018 and held it in 6 quarters.
  • Pier Capital's Viking Therapeutics position peaked at $5.64M in Q3 2024.
  • 373 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2025.

Based on Pier Capital's 13F filing for Q1 2025, filed 13 May 2025.